Effect of brimonidine, measured with the Nerve Fibre Analyser, in patients with acute ischaemic optic neuropathy
| ISRCTN | ISRCTN58221074 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN58221074 |
| Secondary identifying numbers | OZR-2000-07; NTR139 |
- Submission date
- 20/12/2005
- Registration date
- 20/12/2005
- Last edited
- 05/11/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr H G Lemij
Scientific
Scientific
Oogziekenhuis Rotterdam
Schiedamsevest 180
Rotterdam
3011 BH
Netherlands
| Phone | +31 (0)10 401 7777 |
|---|---|
| Lemij@oogziekenhuis.nl |
Study information
| Study design | Randomised, double-blind, placebo controlled, parallel group, two-arm trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study acronym | AION |
| Study objectives | Administration of brimonidine eye drops in patients with acute ischaemic optic neuropathy (AION) reduces loss of vision. |
| Ethics approval(s) | Received from local medical ethics committee |
| Health condition(s) or problem(s) studied | Acute ischaemic optic neuropathy |
| Intervention | Topical treatment with brimonidine (0.5%) eye drops. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Brimonidine |
| Primary outcome measure | Thickness of peripapillary nerve fiber layer. |
| Secondary outcome measures | No secondary outcome measures |
| Overall study start date | 01/02/2001 |
| Completion date | 01/08/2002 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 20 |
| Key inclusion criteria | Arteric or non-arteric AION |
| Key exclusion criteria | 1. Onset of symptoms greater than 5 days ago at presentation 2. Inability to undergo GDx or HFA measurement |
| Date of first enrolment | 01/02/2001 |
| Date of final enrolment | 01/08/2002 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Oogziekenhuis Rotterdam
Rotterdam
3011 BH
Netherlands
3011 BH
Netherlands
Sponsor information
Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)
Hospital/treatment centre
Hospital/treatment centre
Schiedamsevest 180
Rotterdam
3011 BH
Netherlands
| Phone | +31 (0)10 401 77 77 |
|---|---|
| info@oogziekenhuis.nl | |
"ROR" |
https://ror.org/02hjc7j46 |
Funders
Funder type
Research organisation
Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
